Article Sidebar

PDF (Tiếng Việt)
Published: 2025-07-28
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v192i7.3595
Issue
Vol. 192 No. 7 (2025)
Section
Các bài báo
How to Cite
Anh, N. V., Thảo, N. P., Hà, N. T. H., Hà, P. T., Thắm, N. T., & Trang, T. T. T. (2025). 3. A study on the current Tacrolimus usage and therapeutic drug monitoring program in pediatric patients at the Vietnam National Children’s Hospital. Journal of Medical Research, 192(7), 17-29. https://doi.org/10.52852/tcncyh.v192i7.3595

3. A study on the current Tacrolimus usage and therapeutic drug monitoring program in pediatric patients at the Vietnam National Children's Hospital

Nguyen Viet Anh, Nguyen Phuong Thao, Nguyen Thi Hong Ha, Pham Thu Ha, Nguyen Thi Tham, Tran Thi Thu Trang

Main Article Content

Abstract

This retrospective cohort study was conducted on 69 patients at the Vietnam National Children's Hospital from 2020 to 2022 to assess the current usage of tacrolimus (TAC) and the therapeutic drug monitoring program. 22 liver transplant patients , 18 kidney transplant recipients, 25 nephrotic syndrome patients (NS), and 4 systemic lupus erythematosus patients were included in this study. Results showed that the initial TAC dose was around 0.1 mg/kg/day in all groups. There were 27 patients (39.1%) who experienced TAC-related adverse events, of which 63.6% were liver transplant patients (14/27 cases). The highest therapeutic drug monitoring (TDM) frequency in the first two weeks was observed in liver transplant patients (4.2 times/week); however, this group had the lowest proportion of samples within the target range and the highest intra-patient variability, indicating significant fluctuation in TAC levels. The study recommends developing specific TDM guidelines for each indication and strengthening collaboration between clinicians and clinical pharmacists to optimize treatment in pediatric patients.

Article Details

Keywords

Tacrolimus, pediatric, therapeutic drug monitoring, transplantation, nephrotic syndrome

References

1. Spinner JA, Denfield SW. Immunosuppressant Drugs and Their Effects on Children Undergoing Solid Organ Transplant. Pediatr Rev. Feb 1 2022; 43(2): 71-86. doi:10.1542/pir.2020-000620.
2. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clinical pharmacokinetics. Dec 1995; 29(6): 404-30. doi:10.2165/00003088- 199529060-00003.
3. Tờ Thông tin sản phầm Prograf 0.5 mg lưu hành tại Việt Nam
4. Nguyen TVA, Nguyen HD, Nguyen TLH, et al. Higher tacrolimus trough levels and time in the therapeutic range are associated with the risk of acute rejection in the first month after renal transplantation. BMC nephrology. May 8 2023; 24(1): 131. doi:10.1186/s12882- 023-03188-0
5. Nguyễn Thị Quyên, Nguyễn Thị Cúc, Nguyễn Duy Thức, và cộng sự. Phân tích kết quả giám sát nồng độ tacrolimus trong máu trên bệnh nhân sau ghép gan tại bệnh viện Hữu Nghị Việt Đức. Tạp chí Y học Việt Nam. 02/19 2023; 522(1). doi:10.51298/vmj.v522i1.4233
6. Vũ Quang Hợp, Phạm Văn Trân, Hoàng Xuân Sử, Ngô Thu Hằng. Ảnh hưởng của đa hình gen CYP3A5 đến dược động học tacrolimus ở bệnh nhân năm đầu tiên sau ghép thận tại bệnh viện quân y 103. Tạp chí Y học Việt Nam. 07/22 2024; 540(3). doi:10.51298/vmj.v540i3.10499
7. Nedim Hadžić UB, Valérie Anne McLin. Pediatric Liver Transplantation 2021.
8. Hui-Kim Yap ST, Kar- Hui Ng. Pediatric Nephrology On-the-go Fourth 2021.
9. Bộ Y tế. Dược thư Quốc gia Việt Nam. Lần xuất bản thứ ba. Tập II. Nhà xuất bản Khoa học và Kỹ thuật; 2022: 1522-1526.
10. Kershner RP, Fitzsimmons WE. Relationship of fk506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. 1996; 62(7): 920-926.
11. Coste G, Lemaitre F. The Role of Intra-Patient Variability of Tacrolimus Drug Concentrations in Solid Organ Transplantation: A Focus on Liver, Heart, Lung and Pancreas. Pharmaceutics. Feb 8 2022; 14(2).doi:10.3390/pharmaceutics14020379
12. Kelly D. Safety and efficacy of tacrolimus in pediatric liver recipients. Pediatric transplantation. Feb 2011; 15(1): 19-24. doi:10.1111/j.1399-3046.2010.01437.x.
13. Wiesner RH, Fung JJ. Present state of immunosuppressive therapy in liver transplant recipients. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. Nov 2011; 17 Suppl 3: S1-9. doi:10.1002/lt.22410.
14. Schonder KS, Mazariegos GV, Weber RJ. Adverse effects of immunosuppression in pediatric solid organ transplantation. Paediatric drugs. 2010; 12(1): 35-49. doi:10.2165/11316180-000000000-00000.
15. Job KM, Roberts JK, Enioutina EY, et al. Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients. Expert Opin Drug Metab Toxicol. Jul 2021; 17(7): 747-765. doi:10.1080/17425255.2021.1943356.
16. Wang HY, Chan AL, Chen MT, Liao CH, Tian YF. Effects of pharmaceutical care intervention by clinical pharmacists in renal transplant clinics. Transplant Proc. Sep 2008; 40(7): 2319-23. doi:10.1016/j.transproceed.2008.06.050.
17. Griffin SP, Nelson JE. Impact of a Clinical Solid Organ Transplant Pharmacist on Tacrolimus Nephrotoxicity, Therapeutic Drug Monitoring, and Institutional Revenue Generation in Adult Kidney Transplant Recipients. Prog Transplant. Dec 2016; 26(4): 314-321. doi:10.1177/1526924816667950
18. Pallet N, Fernández-Ramos AA, Loriot MA. Impact of Immunosuppressive Drugs on the Metabolism of T Cells. International review of cell and molecular biology. 2018; 341: 169-200. doi:10.1016/bs.ircmb.2018.05.009.
19. Zhang W, Lim LY. Effects of spice constituents on P-glycoprotein-mediated transport and CYP3A4-mediated metabolism in vitro. Drug metabolism and disposition: the biological fate of chemicals. Jul 2008; 36(7): 1283-90. doi:10.1124/dmd.107.019737.
20. Marfo K, Altshuler J, Lu A. Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients. Pharmaceutics. Sep 9 2010; 2(3): 291-299. doi:10.3390/pharmaceutics2030291.